Lyme Disease - Pipeline Assessment and Market Forecasts to 2018

Jan. 13, 2012 - PRLog -- GlobalData estimates that the global Lyme disease market was valued at $46.1m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.2% to reach $80.3m by 2018. The main reason for this limited market revenue is that there are no approved vaccines or drugs in the market for prophylactic or therapeutic management of Lyme disease and only off-label antibiotics are prescribed for treatment of Lyme disease. The antibiotics currently prescribed are doxycycline, amoxicillin, cefuroxime, ceftriaxone, penicillin G, azithromycin and erythromycin. The patent protection of these antibiotics expired long ago and many generic versions are available at low prices. In 2010, the annual cost of therapy for Lyme disease with antibiotics was $298. Another factor contributing to limited market revenue is the low prevalence and incidence rate of the disease in countries like Spain, Italy, the UK and Japan. There are no molecules present in Phase III of the drug development process and thus the late-stage pipeline for the Lyme disease market is weak. There is only one product present in Phase II, which is the product extension of existing off-label antibiotic azithromycin. Even though these drugs will receive regulatory approval in the future for the Lyme disease market, the entry of this product is expected to have a negligible impact on the market in terms of sales value and volume. Despite having a weak late stage pipeline the market is expected to show steady growth, primarily due to an increase in the incidence, diagnosis and treatment rate of the disease particularly in the US, Germany and France.

GlobalData found that the current competition in the Lyme disease therapeutics market is strong. Off-label generic antibiotics are effective against all stages of the disease. The drugs used for the treatment of the early stage of the disease show minimal side effects, while more side effects are observed for the treatment of Chronic Lyme Disease (CLD). The majority of the early-stage patients treated with antibiotics never test positive for Lyme disease again. This indicates that the market is well served by antibiotics. However, antibiotics with a better safety profile are required in the market for the treatment of CLD.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

The competition in the Lyme disease prophylactic market is weak because there are no vaccines or drugs present for prevention of the disease after the discontinuation of GSK’s FDA-approved LYMErix in 2002. Vaccines or drugs with better efficacy and safety profiles than previously launched vaccine LYMErix are required in the Lyme disease prophylactic market.

GlobalData found that the pipeline for the Lyme disease market is weak. There are only five therapies in the current pipeline, four of which are first-in-class in the pre-clinical stage of the drug development process. One product extension of existing off-label antibiotic azithromycin is present in Phase II of clinical development. GlobalData estimates that the entry of this molecule will not result in a significant increase in the Lyme disease market.

GlobalData, the industry analysis specialist, has released its new report, “Lyme Disease – Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Lyme disease therapeutics market. The report identifies the key trends shaping and driving the global Lyme disease therapeutics market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Lyme disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Lyme...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.